New cocktail shows promise for Hard-to-Treat myeloma
NCT ID NCT03361306
First seen Feb 02, 2026 · Last updated May 21, 2026 · Updated 16 times
Summary
This study tested a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and elotuzumab) in 15 people whose multiple myeloma had returned or stopped responding to treatment. The goal was to see if this mix could shrink tumors or eliminate signs of cancer. While some patients achieved a very good partial response or better, this is not a cure—patients still need ongoing treatment to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.